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ABSTRACT
Background: Pneumonia is the most common complication of varicella-zoster infection in adults and
has potentially devastating effects when complicating pregnancy. Due to the significant morbidity
and mortality associated with this complication during pregnancy and the small number of reported
cases in the literature, we present this report to help educate physicians who care for pregnant
women.
Cases: Seven patients are presented in this report. These patients presented at various stages in
pregnancy, from 17 to 31 weeks of gestation. Three of the patients had unremarkable hospital
courses. Three of the patients had hospital stays over 21 days in duration. One patient died from
complications of varicella pneumonia after 31 days of hospitalization. The obstetric outcomes of the
7 patients described include 1 non-viable delivery at 20 weeks gestation, 3 term deliveries, 2 preterm
deliveries, and 1 patient who has not yet delivered. All of the patients presented were treated with
intravenous acyclovir therapy. Of the patients described, 3 required intubation and ventilatory
support. Other complications encountered include disseminated intravascular coagulation (DIC),
adult respiratory distress syndrome (ARDS), metabolic encephalopathy, pneumothorax, superim-
posed bacterial pneumonia, and sepsis.
Conclusion: The course and treatment of varicella pneumonia complicating pregnancy are dis-
cussed. Current recommendations regarding the use of varicella-zoster immune globulin (VZIG)
are also reviewed. Infect. Dis. Obstet. Gynecol. 4:338-346, 1996. (C) 1997 Wiley-Liss, Inc.
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lrimary varicella-zoster infection in pregnancy is
estimated to occur in 1-5/10,000 pregnancies. 1,z
Though commonly a mild infection in children,
varicella-zoster infection in adults is associated
with higher morbidity and mortality. The most
common complication of varicella infection in
adults is pneumonia. Approximately 16% of adults
with varicella infection will demonstrate evidence
of pulmonary involvement, e Although the inci-
dence of varicella pneumonia does not appear to be
increased in pregnancy, it is well established that
the morbidity and mortality from this infection in
pregnancy are higher. Mortality from varicella
pneumonia complicating pregnancy is reported to
be as high as 41%.3 In our institution over the past
5 years, we have observed 7 cases of varicella pneu-
monia complicating pregnancy, which we now pre-
sent with a discussion of the pertinent literature.
Table presents a summary of the salient features
of each case and Table 2 presents initial laboratory
data.
CASE REPORTS
Case
C.H. was a 35-year-old white female gravida 2, para
1, with an intrauterine pregnancy at 25 weeks ges-
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TABLE I. Patient and case characteristics
SCHUTTE ET AL.
Duration
of IV Antibiotics
Length acyclovir used
Gestational of therapy in (dosages--
age at hospital Acyclovir days (days IV unless
Case presenta- stay dose of oral otherwise
no. tion (weeks) (days) (mg/kg) dosing specified)
Mechanical
ventilation VZIG
required use
Fetal
outcome
Maternal
complications
25-26 10 12.0 9 (0) None No No
2 17-18 32 12.4
3 20-21 31 6.5 increased
to 10.0
8 (0) Erythromycin Yes No
(I gq6 x
5 days)
Vancomycin
(I.25 g q 12
x 16 days)
Pipericillin (4
gq4x
7 days)
Tobramycin
(I 10 mg q
12 x 5 days
Ceftazidime
(2gq8 x
8 days)
10 (0) Erythromycin Yes No
(I gq6
x day)
4 30-31 22 12.5 7 (0) Cefuroxime Yes Yes
(I.0gq 8x
8 days)
Vancomycin
(I.25 g q 12
x 10 days)
Tobramycin
(100 mg q
12x
10 days)
Ceftazidime
(I.0gq 8x
10 days)
5 27-28 21 5.0 5 (5) Ceftriaxone (2 No No
gq8x
3 days)
Clarithromycin
(500 mg po
bid x 9 days)
6 30-31 3 10.3 3 (5) None No No
7 23-24 5 10.0 5 (5) Cefazolin (2 g No No
q8x
4 days)
Term SVD,
normal
male
Term SVD,
normal
male
SVD of
non-viable
male
(normal)
PTD by
cesarean
section,
normal
female
PTD by
cesarean
section,
normal
male
Term SVD,
normal
female
Term SVD,
normal
female
None
ARDS, seizure
disorder,
superimposed
bacterial
pneumonia,
staphylococcal
septicemia,
metabolic
encephalopathy,
cholelithiasis,
sinusitis
Maternal death,
DIC, ascites,
pneumothorax,
superimposed
candidal
pneumonitis
ARDS,
staphylococcal
septicemia
None
None
Subsequent
bacterial
pneumonia
requiring
2-day
hospitalization
in third
trimester
alV, intravenous; SVD, spontaneous vaginal delivery; PTD, preterm delivery; ARDS, adult respiratory distress syndrome; DIC, disseminated intravascular
coagulation.
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TABLE 2. Descriptive laboratory data
Case Hgb % %
No. (mg/dl) WBC Segs Bands
Arterial Varicella
pH pO2 pCO2 SAO2 serology
0.6 10,900 50 24
3.0 5,700 70 0
1.6 13,900 85 0
1.0 5,400 83 30
2.8 4,000 73 7
2.4 8,400 91 0
1.0 7,500 65 15
7.448 68 30 95 Unavailable
7.419 40 33 76 Positive
7.446 50 32 87 Positive
7.495 84 28 97 Unavailable
7.405 80 34 96 Negative
7.476 72 31 96 Negative
7.481 61 25 93 Positive
aHgb, hemoblobin; Segs, segmented neutrophils.
tation who presented with a 3-day history of leth-
argy, pruritic vesicular rash (involving the trunk,
face, and extremities), non-productive cough, and
progressively worsening shortness of breath. Her
past medical history was significant for exposure to
a child with documented varicella infection 2
weeks prior to initial presentation and tobacco use.
Initial physical examination revealed tachycardia,
tachypnea, a temperature of 36.7C, scattered
rhonchi bilaterally on auscultation of the lungs, and
a diffuse vesicular rash involving the skin and oro-
pharynx. The admission chest X-ray revealed dif-
fuse bilateral air space densities consistent with
varicella pneumonia. An obstetric ultrasound on
presentation revealed a viable fetus with no evi-
dence of fetal anomalies. The patient was started
on intravenous acyclovir, oxygen (FiOz0.50) by
ventimask, intermittent positive pressure breath-
ing, and aggressive pulmonary toilet. All viral, bac-
terial, and mycoplasma cultures were negative. She
improved, was discharged, and returned at 41
weeks gestation to have an uncomplicated sponta-
neous vaginal delivery of a normal male infant
weighing 3,039 g.
Case 2
Y.B. was a 21-year-old white female gravida 4, para
2, who presented at 17 weeks gestation with a
4-day history of cough, rash, malaise, fever, emesis,
and shortness of breath. Her past medical history
was significant for tobacco use, varicella infection
at age 5 years, and recent exposure to a child with
varicella-zoster infection. Physical examination re-
vealed a mild tachycardia, tachypnea, a tempera-
ture of 39.2C, fine crackles bilaterally on auscul-
tation of the lungs, and vesicular rash present over
the face, chest, back, and oropharynx. The initial
chest X-ray revealed a severe, patchy, and diffuse
alveolar infiltrate (Fig. 1). She was admitted with a
diagnosis of varicella pneumonia and started on
acyclovir. She was intubated on the 2nd hospital
day and required prolonged ventilatory support.
Her hospital course was complicated by adult re-
spiratory distress syndrome (ARDS), tonic-clonic
seizures requiring intravenous phenytoin, superim-
posed bacterial pneumonia, staphylococcal septice-
mia, metabolic encephalopathy, thrombocytopenia,
anemia, cholelithiasis, sinusitis, elevated liver en-
zymes, requirement for enteral nutrition, and ane-
mia requiring transfusion of 6 units of packed red
blood cells. An obstetric ultrasound revealed a vi-
able intrauterine pregnancy with no evidence of
fetal anomalies. The remainder of her prenatal care
was uncomplicated. She was discharged and re-
turned at 41 weeks gestation to have a spontaneous
vaginal delivery of a normal male infant weighing
2,869 g.
Case 3
T.M. was a 19-year-old white female gravida 2,
para 1, who presented at 20 weeks gestation with a
2-day history of malaise, nausea, emesis, fever,
mild abdominal pain, and diffuse vesicular rash.
The patient denied any pulmonary symptoms. Her
past medical history was unremarkable with the
exception of exposure to varicella-zoster infection 2
weeks prior to the onset of her symptoms. Initial
physical examination revealed tachycardia, mild
tachypnea, a temperature of 37.8C, and diffuse
vesicular lesions consistent with varicella in various
stages of eruption scattered over her face, trunk,
and extremities. Auscultation of the lungs revealed
normal findings without adventitious lung sounds.
Within 24 h of admission, the patient developed
symptoms of cough, shortness of breath, and a tem-
perature of 38.6C. A chest X-ray was consistent
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Fig. I. Admission chest radiograph of case 2 demonstrating a severe, patchy, and diffuse alveolar infiltrate consistent with
varicella pneumonia.
with diffuse pneumonitis or ARDS (Fig. 2). She
was started on 100% oxygen by non-rebreather
mask, acyclovir, and erythromycin. Within 24 h, her
breathing became more labored requiring intuba-
tion and ventilatory support. On the 3rd hospital
day, the patient developed disseminated intravas-
cular coagulation (DIC). She was noted to have
vaginal bleeding on this day and a cervical exami-
nation revealed 3 cm dilatation with bulging mem-
branes. Given clinically worsening DIC, a prostin
induction was begun to expedite delivery. She de-
livered a non-viable fetus 10 h later. Following de-
livery, the patient’s condition further deteriorated
necessitating inverse inspiratory-to-expiratory ven-
tilatory support, invasive hemodynamic monitor-
ing, vasopressor support, total parenteral nutrition,
and multiple transfusions of blood components.
Her hospital course was further complicated by as-
cites, cholecystitis with subsequent cholecystecto-
my, pneumothorax, tracheostomy secondary to pro-
longed ventilator dependence, and candidal pneu-
monitis requiring treatment with intravenous
amphotericin B. She died 31 days after admission.
Virologic studies and autopsy revealed that the pa-
tient expired with varicella pneumonia, ARDS,
varicella hepatitis, and DIC.
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Fig. 2. Admission chest radiograph of case 3 demonstrating findings consistent with diffuse pneumonitis (ARDS).
Case 4
T.K. was a 20-year-old white female gravida 1, para
0, at 30 4/7 weeks gestation who presented with a
2-day history of fever, malaise, myalgias, produc-
tive cough with increasing dyspnea, and a vesicular
rash present over the face, trunk, and upper ex-
tremities. Her past medical history was significant
for tobacco use and stage III Hodgkin’s disease
which had been in remission for 2 years prior to
presentation. Initial physical examination revealed
tachycardia, tachypnea, a temperature of 38.2C,
moderate amount of dyspnea, bilateral wheezing
on auscultation, and diffuse vesicular lesions pre-
sent on the face, trunk, and extremities. Chest X-
ray revealed diffuse, bilateral coarse nodular pneu-
monia. The patient was started on intravenous acy-
clovir and cefuroxime. Despite albuterol aerosol
treatments and aggressive pulmonary toilet, she
became more hypoxic requiring intubation and
ventilatory support. A repeat chest X-ray revealed
pneumonia with evidence ofARDS. She was given
varicella-zoster immune globulin (VZIG; 625 units
intramuscularly) secondary to her immunocompro-
mised status and probable preterm delivery. Pre-
term labor was confirmed, and she was started on
intravenous magnesium sulfate for tocolysis. On
hospital day 10, the patient began to appear septic,
and was started on broad spectrum antibiotics. She
was delivered of a normal female infant by primary
low transverse cesarean section secondary to non-
reassuring fetal assessment by non-stress test, bio-
physical profile, and contraction stress test. The
infant had Apgar scores of 2 and 5 at and 5 min,
respectively, and a weight of 2,015 g. Her condition
slowly improved, and she was extubated on post-
operative day 9 and discharged from the hospital on
postoperative day 12.
Case 5
L.F. was a 32-year-old white female gravida 5, para
3, who presented at 27 5/7 weeks gestation with a
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1-week history of dyspnea cough productive of
green sputum. She related a 1-day history of a ve-
sicular rash present on her trunk and face. She had
recent exposure to varicella infection. The pa-
tient’s past medical history was significant for
asthma, chronic bronchitis, and insulin-requiring
gestational diabetes mellitus. She denied any to-
bacco use. Initial physical examination revealed a
temperature of 38.1C, mild tachycardia, tachy-
pnca, weight of 175.5 kg, mild respiratory distress,
diffuse wheezing throughout both lung fields, and
vesicular lesions scattered over her face, neck, and
trunk. Chest X-ray revealed a diffuse interstitial
process bibasilarly consistent with varicella pneu-
monia. Initial obstetric ultrasound revealed a viable
singleton fetus with decreased amniotic fluid vol-
ume, but no apparent fetal anomalies. Varicella an-
tibody studies, comprehensive viral studies, spu-
tum culture, and acid-fast bacilli (AFB) studies
were all negative. The patient was admitted and
started on ceftriaxone, acyclovir, oral clarithromy-
cin, subcutaneous heparin, and intravenous ami-
nophylline. Her hospital course was unremarkable
except for the development of thrombocytopenia,
which was attributed to her viral syndrome after
pregnancy-induced hypertension was excluded. At
32 weeks gestation, she was delivered by low ver-
tical cesarean section secondary to decreased fetal
movement, a positive contraction stress test, severe
oligohydramnios, and the inability to effectively
monitor the patient due to obesity. She was deliv-
ered of a normal male infant weighing 1,097 g, with
Apgar scores of 5 and 9 at and 5 min, respectively.
The patient had an uncomplicated postpartum
course.
Case 6
L.H. was a 34-year-old female gravida 4, para 3,
who presented at 30 weeks gestation with a 2-day
history of pruritic rash followed by the develop-
ment of fever, chills, dyspnea, and non-productive
cough. Her past medical history was unremarkable
except for exposure to varicella infection 2 weeks
before presentation. She denied any history of to-
bacco use. Initial physical examination revealed a
temperature of 39.4C, mild tachycardia, mild
tachypnea, and rales present at the posterior base
of the left lung. She was noted to have an extensive
maculopapular rash with lesions in various stages
from pustules to scarred lesions involving the face,
neck, trunk, abdomen, back, extremities, and oro-
pharynx. Chest X-ray revealed a diffusely nodular
interstitium with a left lower lobe infiltrate and
small bilateral pleural effusions. Blood cultures,
sputum cultures, varicella antibody studies, and
comprehensive viral studies were all negative. The
patient was treated with intravenous acyclovir and
was discharged without complications. She subse-
quently presented at 38 weeks gestation to have an
uncomplicated spontaneous vaginal delivery of a
normal female infant weighing 4,275 g.
Case 7
L.B. was a 18-year-old white primigravid female
with an intrauterine pregnancy at 23 weeks gesta-
tion who presented with a history of chest conges-
tion, vesicular skin rash, fever, productive cough,
and progressively worsening shortness of breath.
Her past medical history was unremarkable with
the exception of exposure to varicella-zoster infec-
tion 2 weeks prior to the onset of her symptoms
and tobacco use. Initial physical examination re-
vealed a temperature of 37.6C, tachycardia, mild
tachypnea, and diffuse vesicular rash present on
the face, trunk, extremities, abdomen, and back.
Auscultation of the lungs revealed only fair air ex-
change with few bibasilar rales. Initial chest X-ray
revealed bilateral patchy nodular infiltrates consis-
tent with varicella pneumonia. An obstetric ultra-
sound revealed a viable female fetus with no evi-
dence of fetal anomalies. The patient was admitted
with a diagnosis of varicella pneumonia. She re-
ceived acyclovir, oxygen (2 by nasal cannula),
VZIG, aerosol treatments, and cefazolin for a con-
comitant urinary tract infection. The patient recov-
ered without complications. All viral, bacterial, and
mycoplasma cultures were reported as negative.
The patient returned at term to have an uncompli-
cated spontaneous vaginal delivery of a normal fe-
male infant weighing 3,033 g.
DISCUSSION
Varicella, which is caused by a DNA virus, is usu-
ally a highly contagious benign childhood disease.
In adults the illness is less common but usually
more severe. Because varicella infection is highly
contagious, it is estimated that only 5% of repro-
ductive age women lack IgG antibody.4 Only 2% of
reported cases occur after the age of 20 years, but
25% of deaths from varicella are in this age group,s
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The most common complication is varicella pneu-
monitis, occurring in 14-50% of adults with a mor-
tality rate of 3-11%.6,7
The incidence of varicella infection in preg-
nancy is 1-7/10,000 pregnancies. 1,s Varicella infec-
tion is considered to be more severe in pregnancy,9
with a mortality from varicella pneumonia esti-
mated to be as high as 44% in pregnant women
compared to 11% in non-pregnant women.3,4,6 The
mortality from varicella-zoster pneumonia is high-
est if infection occurs in the third trimester. This
increased risk of fatality is postulated to be second-
ary to advancing immmunosuppression during later
pregnancy though this has never been proved,z,l
In the cases presented, all women had infection in
the second and third trimesters, with the only ma-
ternal death occuring in the early second trimester.
Fetal complications of varicella-zoster infection
in pregnancy include premature delivery, fetal vari-
celia syndrome, congenital zoster of infancy, and
neonatal varicella.3,1-14 Fetal varicella syndrome
occurs when a fetus is exposed to varicella infection
in the first trimester of pregnancy and is character-
ized by low birth weight, cutaneous scars, hypotro-
phic limbs, ocular abnormalities including chorio-
retinitis, cataracts, microphthalmia, and Horner’s
syndrome, brain damage, and mental retardation. 7,9
The exact incidence of this complication is un-
known but has been estimated as 3-6% by prospec-
tive studies.8,11,1e Neonatal varicella is most com-
mon and severe when maternal infection occurs
within 4 days of delivery or 48 h following deliv-
ery. 7,9 This increased severity related to time of
delivery is thought to be secondary to a lack of
passive immunity from maternal antibodies.9 Neo-
natal varicella infection is associated with compli-
cations including pneumonia, hepatitis, thrombo-
cytopenia, arthritis, conjunctivitis, carditis, and ne-
phritis, and is estimated to have a case fatality rate
of 30-50%.7,9 None of the neonates presented de-
veloped any evidence of varicella infection or fetal
varicella syndrome.
Acyclovir is a nucleoside analogue that inhibits
replication of herpes virus DNA synthesis. Is Acy-
clovir is a category C medication and therefore
should not be used in pregnancy unless the poten-
tial therapeutic benefits outweigh the potential
risks to the fetus.6 Acyclovir does cross the pla-
centa and is found in amniotic fluid and fetal tis-
sue, though no teratogenic effects have been ob-
served in 241 pregnant women exposed over 6
years experience with this agent.
6 The first use of
intravenous acyclovir in pregnancy for treatment of
varicella pneumonia was reported in 1986.17 Prior
to the use of acyclovir for varicella pneumonia in
pregnancy, the mortality was 36-41%.3,4 A signifi-
cant reduction in mortality to 13% has been re-
ported since the advent of acyclovir therapy in the
treatment of varicella pneumonia.
4 The exact dos-
ages reported in studies have varied from 5 to 30
mg/kg. 17-zz. The dose usually recommended by in-
fectious disease experts for treating disseminated
varicella-zoster infections in immunocompromised
patients is 10-15 mg/kg given 3 times daily for 7
days.z-z6 It should be noted that the one maternal
death in our case series involved a patient who had
initially received a low dose of acyclovir (6.5 mg/kg
later increased to 10 mg/kg), though whether this
contributed to her death is unclear.
VZIG is a product which contains varicella-
zoster immunoglobulin G and is derived from the
plasma of normal volunteer blood donors with high
titers of the antibody,s,z7 VZIG has been available
in the United States since 1978 and is commonly
used successfully to treat infants exposed to vari-
cella infection. It is also indicated in immunocom-
promised individuals and pregnant patients with no
known history of infection and an unknown anti-
body status when exposed to varicella infection,s
VZIG should be administered within 96 h of expo-
sure to varicella to be effective, z7 When VZIG
(adult dose 625 units intramuscularly) is adminis-
tered to exposed adults, it has been shown to pre-
vent or attenuate the course of infection,zT’e8 but it
has not been shown to prevent congenital or neo-
natal varicella,s
Varicella vaccine (Varivax) is a live attenuated
vaccine which became available in the United
States in 1995.e9 The recommended dosage of this
vaccine is two intramuscular injections of 0.5 ml
given 4-8 weeks apart,e9 In adults, two doses of
vaccine are required to achieve a seroconversion
rate of greater than 90%.3 It has been proposed
that limitations in adult helper T-cell response to
varicella-zoster virus antigens are responsible for
this observation.3 The persistence of antibodies 10
years after vaccination is 95% in healthy children
and 75% in adults.z Side effects from the vaccina-
tion occur in 5-10% of those vaccinated and usually
consists of a mild rash.z Routine use of this vac-
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cine will hopefully reduce the number of suscep-
tible women entering pregnancy thereby decreas-
ing the number of congenital/neonatal infections
and the risk of significant morbidity and mortality
associated with primary varicella infection in preg-
nancy. None of the patients presented in this re-
port received the varicella vaccine.
In conclusion, primary maternal varicella-zoster
infection in pregnancy is associated with significant
morbidity and mortality as demonstrated by the
cases presented in this report. Given the potential
severity of this disease in pregnancy, routine ante-
natal screening for varicella antibodies and postpar-
tum immunization similar to that of current rubella
immunization practices should be considered.
Theoretically, this practice would lower the risks of
congenital varicella syndrome, neonatal herpes zos-
ter, neonatal varicella infection, and maternal mor-
bidity and mortality by decreasing the number of
primary infections during pregnancy. The cost ef-
fectiveness of such an immunization progr.am will
need to be researched, but as evident from our case
studies, the consequences of varicella-zoster infec-
tion in pregnancy can be devastating. The financial
burden of caring for women with serious varicella
infection in pregnancy also needs to be considered
when evaluating the cost effectiveness and benefit
of a routine screening and vaccination program.
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